| Objective: To investigate the effect and short-term efficacy of sacuba valsartan sodium on cerebral natriuretic peptide and troponin in patients with acute myocardial infarction and heart failure.Methods: 60 patients with acute myocardial infarction complicated with heart failure were randomly divided into two groups: Benazepril hydrochloride group and Sarkobatrivalsartan sodium group.Each group had 30 patients respectively.Patients in each group were treated with conventional drugs such as crown expansion,anti-embolism and diuresis.On this basis,a group of patients were given benazepril hydrochloride orally.BNP and c Tn I decreased after 1 week,and LVDS,LVDD and LVEF were compared between the two groups after 1 week and 12 weeks.Results:There was no statistical difference in plasma BNP level between the two groups before treatment.After 1 week of systematic treatment,the plasma BNP level of each group decreased.Serum BNP lowering level(0.26 ± 0.18)g/l in Shakuba valsartan sodium group was significantly higher than that in the control group(0.35 ± 0.14)g/l.There was no statistical difference in the serum troponin level between the two groups of patients after admission to hospital and there was no difference before treatment.All the levels were decreased after one week of systematic treatment.Plasma troponin(0.183 ±0.146)ng/ml in the sarkobatrivaltan sodium group,significantly higher than the reduced level of 0.203 ± 0.147)ng/ml in the benazepril hydrochloride control group.There was no statistical difference in cardiac color Doppler ultrasound results between the two groups before treatment.However,the LAD of left ventricle and LAD of left ventricle(50.36 ± 9.54)mm and(42.26 ± 7.31)mm after treatment of 1 week were significantly lower than those of the control group(Benazepril Hydrochloride)in patients with left ventricular diastolic end-end diameter and left ventricular systolic end diameter(50.36± 9.54)mm).Left ventricular final systolic diameter(53.51 ± 11.32)mm,(48.18 ± 6.34)mm,and left ventricular ejection fraction(50.71 ± 4.46)%,is significantly higher than that of the benazepril hydrochloride control group(37.28 ± 10.34)%.Echocardiographic examination of end-of-diastolic diameter of left ventricle in patients in thesarkobatrazadine sodium group after 12 weeks of treatment,Left ventricular end-systolic IAD(47.33 ± 8.56)mm,(38.36 ± 6.42)mm are significantly lower than left ventricular end-diastolic IAD and left ventricular end-systolic IAD(51.37 ± 11.41)mm,(40.72 ± 10.18)mm in the control group of benazepril hydrochloride,Left Ventricular Ejection Fraction(58.31 ± 7.54)% in the Shakuba Valsartan Sodium Group is significantly higher than left ventricular ejection fraction(47.59 ± 5.48)% in benazepril hydrochloride control group.Comparing these data,we can see that Shakubat Valsartan Sodium can significantly reduce LVDs and LVDd and increase LVEF in the treatment of patients with acute myocardial infarction complicated with heart failure,and its clinical effect is better than that of traditional ACEI drugs.It can improve the middle and long term prognosis of the patients,and is worth popularizing in the clinic.Conclusion: Compared with routine anti-heart failure drug benazepril,oral sakouba valsartan sodium can significantly improve the prognosis of patients with acute myocardial infarction complicated with heart failure. |
PDF Full Text Request